EP4484556A3 - Compositions et procédés pour l'ingénierie in vitro du génome viral - Google Patents

Compositions et procédés pour l'ingénierie in vitro du génome viral Download PDF

Info

Publication number
EP4484556A3
EP4484556A3 EP24195039.3A EP24195039A EP4484556A3 EP 4484556 A3 EP4484556 A3 EP 4484556A3 EP 24195039 A EP24195039 A EP 24195039A EP 4484556 A3 EP4484556 A3 EP 4484556A3
Authority
EP
European Patent Office
Prior art keywords
vitro
viral
engineering
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24195039.3A
Other languages
German (de)
English (en)
Other versions
EP4484556A2 (fr
Inventor
Kyle C. Cady
E. Magda BARBU
Christen G. Dipetrillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
C3J Therapeutics Inc
Original Assignee
C3J Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C3J Therapeutics Inc filed Critical C3J Therapeutics Inc
Publication of EP4484556A2 publication Critical patent/EP4484556A2/fr
Publication of EP4484556A3 publication Critical patent/EP4484556A3/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
EP24195039.3A 2014-12-16 2015-12-15 Compositions et procédés pour l'ingénierie in vitro du génome viral Pending EP4484556A3 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462092707P 2014-12-16 2014-12-16
US201562102362P 2015-01-12 2015-01-12
US201562242811P 2015-10-16 2015-10-16
EP15870907.1A EP3234136B1 (fr) 2014-12-16 2015-12-15 Compositions et procédés de modification in vitro de génomes viraux
PCT/US2015/065891 WO2016100389A1 (fr) 2014-12-16 2015-12-15 Compositions et procédés de modification in vitro de génomes viraux

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP15870907.1A Division EP3234136B1 (fr) 2014-12-16 2015-12-15 Compositions et procédés de modification in vitro de génomes viraux

Publications (2)

Publication Number Publication Date
EP4484556A2 EP4484556A2 (fr) 2025-01-01
EP4484556A3 true EP4484556A3 (fr) 2025-05-07

Family

ID=56127485

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15870907.1A Active EP3234136B1 (fr) 2014-12-16 2015-12-15 Compositions et procédés de modification in vitro de génomes viraux
EP24195039.3A Pending EP4484556A3 (fr) 2014-12-16 2015-12-15 Compositions et procédés pour l'ingénierie in vitro du génome viral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP15870907.1A Active EP3234136B1 (fr) 2014-12-16 2015-12-15 Compositions et procédés de modification in vitro de génomes viraux

Country Status (9)

Country Link
US (4) US10221398B2 (fr)
EP (2) EP3234136B1 (fr)
JP (2) JP6842417B2 (fr)
CN (2) CN113215115B (fr)
AU (2) AU2015362618B2 (fr)
CA (2) CA3254091A1 (fr)
EA (1) EA038595B1 (fr)
ES (1) ES2991077T3 (fr)
WO (1) WO2016100389A1 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
JP6261500B2 (ja) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ ヌクレアーゼ切断特異性の評価および改善
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
HUE049405T2 (hu) 2014-06-23 2020-09-28 Regeneron Pharma Nukleáz-közvetített DNS-összeállítás
WO2016022363A2 (fr) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Protéines cas9 comprenant des intéines dépendant de ligands
EP3234136B1 (fr) 2014-12-16 2024-08-21 C3J Therapeutics, Inc. Compositions et procédés de modification in vitro de génomes viraux
US20160362667A1 (en) * 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
US10513732B2 (en) * 2015-07-13 2019-12-24 New York University Sequencing methods and kits
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
US10136820B2 (en) * 2015-12-21 2018-11-27 Gholam A. Peyman Method to visualize very early stage neoplasm or other lesions
US11433260B2 (en) 2015-12-21 2022-09-06 Gholam A. Peyman Cancer treatment methods using thermotherapy and/or enhanced immunotherapy
WO2017172645A2 (fr) * 2016-03-28 2017-10-05 The Charles Stark Draper Laboratory, Inc. Méthodes de modification génétique de bactériophages
KR102547316B1 (ko) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
DK3503915T5 (da) 2016-08-26 2024-09-02 Telesis Bio Inc Genetisk modificerede Vibro natriegen
EP3526320A1 (fr) 2016-10-14 2019-08-21 President and Fellows of Harvard College Administration d'aav d'éditeurs de nucléobases
WO2018071841A1 (fr) * 2016-10-14 2018-04-19 The Forsyth Institute Compositions et procédés d'évitement de mécanismes de défense bactérienne
WO2018119359A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih
WO2018148412A1 (fr) 2017-02-09 2018-08-16 The Charles Stark Draper Laboratory Inc. Bactériophages k1-5 recombinants et leurs utilisations
EP3592846A1 (fr) 2017-03-06 2020-01-15 Massachusetts Institute of Technology Procédés de clonage de prophages et de production de particules de phage lytique
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
EP3592853A1 (fr) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression de la douleur par édition de gène
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
CA3057192A1 (fr) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Editeurs de nucleobase comprenant des proteines de liaison a l'adn programmable par acides nucleiques
WO2018209320A1 (fr) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
WO2018222891A1 (fr) * 2017-06-01 2018-12-06 The Charles Stark Draper Laboratory Inc. Ingénierie de phages: protection par intermédiaire circularisé
WO2019023680A1 (fr) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace)
US10174295B1 (en) * 2017-08-01 2019-01-08 The Charles Stark Draper Laboratory, Inc. Composition of matter: engineering of Escherichia coli phage K1E
WO2019032576A2 (fr) * 2017-08-08 2019-02-14 The Charles Stark Draper Laboratory Inc. Manipulation de bactériophages par semi-synthèse
EP3676376B1 (fr) 2017-08-30 2025-01-15 President and Fellows of Harvard College Éditeurs de bases à haut rendement comprenant une gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019118949A1 (fr) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systèmes et procédés de prédiction des résultats de la réparation en ingénierie génétique
CN112236517A (zh) * 2018-05-22 2021-01-15 学校法人自治医科大学 抗菌噬菌体、治疗用组合物、杀菌剂、食品、细菌鉴别试剂盒、治疗用组合物制造方法、细菌去除方法、细菌鉴别方法及动物治疗方法
EP3797160A1 (fr) 2018-05-23 2021-03-31 The Broad Institute Inc. Éditeurs de bases et leurs utilisations
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020092453A1 (fr) 2018-10-29 2020-05-07 The Broad Institute, Inc. Éditeurs de nucléobases comprenant geocas9 et utilisations associées
WO2020092748A1 (fr) * 2018-11-01 2020-05-07 The Trustees Of Princeton University Système d'inactivation de protéines et de phages recombinants pour la destruction bactérienne ciblée, l'infection, la biodétection et comme moyen d'extraction de protéines
EP4374923A3 (fr) * 2018-11-27 2024-08-14 Eligo Bioscience Protéines de liaison à un récepteur chimérique pour utilisation dans des véhicules d'administration bactérienne
KR20210107053A (ko) * 2018-12-21 2021-08-31 엘리고 바이오사이언스 박테리아 전달 비히클에서 사용을 위한 분지형 수용체 결합 다수-서브유닛 단백질 복합체
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020163655A1 (fr) 2019-02-06 2020-08-13 Fred Hutchinson Cancer Research Center Bactéries productrices de minicercle conçues pour produire de manière différentielle des molécules d'acide nucléique à l'intérieur de celles-ci
JP7657726B2 (ja) 2019-03-19 2025-04-07 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
WO2020206134A1 (fr) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Procédés pour l'introduction sans cicatrice de modifications ciblées dans des vecteurs de ciblage
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
CN114540389B (zh) * 2020-11-26 2024-05-14 深圳华大生命科学研究院 一种制备基因工程病毒的方法及其应用
CN112778399A (zh) * 2021-01-21 2021-05-11 南开大学 一类源自毒性淀粉样纤维纳米抗菌肽的制备及性质表征方法
JP2022117439A (ja) * 2021-01-29 2022-08-10 学校法人立教学院 インビトロパッケージングを用いた多断片ｄｎａの連結および細胞内導入方法
WO2022251644A1 (fr) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Cellules immunitaires déficientes en nr4a3 et leurs utilisations
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
KR20240042484A (ko) * 2021-08-02 2024-04-02 아마타 파마슈티컬스, 인크. 향상된 항균 활성을 갖는 박테리오파지
CN113755451B (zh) * 2021-09-03 2023-06-06 广西大学 一株大肠杆菌噬菌体gn6及其应用
EP4248987A1 (fr) * 2022-03-21 2023-09-27 Nomad Bioscience GmbH Bactériocines chimériques et procédé de lutte contre les pseudomonas
KR20250027283A (ko) 2022-05-19 2025-02-25 라이엘 이뮤노파마, 인크. nr4a3을 표적하는 폴리뉴클레오타이드 및 이의 용도
WO2024064952A1 (fr) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a surexprimant c-jun
WO2024064958A1 (fr) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a
WO2024077174A1 (fr) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a
WO2025208072A1 (fr) * 2024-03-29 2025-10-02 The General Hospital Corporation Méthodes et matériaux pour le traitement de troubles liés à des infections bactériennes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012036580A2 (fr) * 2010-09-17 2012-03-22 Tecnifar-Indústria Técnica Farmacêutica, S.A. Phage antibactérien, peptides phagiques et leurs procédés d'utilisation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877279A (en) * 1994-10-13 1999-03-02 Nanoframes, Llc Materials for the production of nanometer structures and use thereof
WO1999023107A1 (fr) * 1997-10-31 1999-05-14 Maxygen, Incorporated Modification du tropisme viral et de la diversite d'especes hote par recombinaison du genome viral
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9809414D0 (en) 1998-05-02 1998-07-01 Scottish Crop Research Inst Method
US7019122B1 (en) 1998-10-30 2006-03-28 Janssen Pharmaceutica N.V. Unusual retrotransposon from the yeast Candida albicans
ES2252263T3 (es) * 2000-07-25 2006-05-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Bacteriofago que tiene una gama de hospedadores multiple.
WO2006021944A1 (fr) 2004-08-12 2006-03-02 Leanway Automatic Areanas Ltd. Configuration de structure de base de donnees amelioree
US8182804B1 (en) * 2004-09-13 2012-05-22 Trustees Of Boston University Engineered enzymatically active bacteriophages and methods of uses thereof
EP1828390B1 (fr) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Vecteurs chimeriques
US20070004041A1 (en) 2005-06-30 2007-01-04 Codon Devices, Inc. Heirarchical assembly methods for genome engineering
DE602006015701D1 (de) 2005-12-29 2010-09-02 Abl Biotechnologies Ltd Neuer schizochytrium-limacinum-stamm, der sich für die produktion von lipiden und extrazellulären polysacchariden eignet, sowie verfahren hierfür
US8216844B2 (en) 2006-08-29 2012-07-10 Danisco Us Inc. Compositions and methods for improved protein production
EP2147113A1 (fr) 2007-05-23 2010-01-27 Cognis IP Management GmbH Souches dérivées de haematococcus pluvialis permettant la production efficace d'astaxanthine
GB0715416D0 (en) * 2007-08-07 2007-09-19 Phico Therapeutics Ltd Modified bacteriophage
CA2711841A1 (fr) 2008-01-10 2009-09-03 Trustees Of Boston University Bacteriophage modifie en tant qu'adjuvants pour des agents antimicrobiens et compositions et procedes d'utilisation de ceux-ci
AU2009214435C1 (en) 2008-02-15 2014-07-17 Synthetic Genomics, Inc. Methods for in vitro joining and combinatorial assembly of nucleic acid molecules
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
CN101928670B (zh) 2009-09-24 2012-02-22 上海天伟生物制药有限公司 一种抗生素的高产菌株及其制备方法和用途
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
SG10201606285YA (en) * 2012-02-01 2016-09-29 Synthetic Genomics Inc Materials and methods for the synthesis of error-minimized nucleic acid molecules
EP3241902B1 (fr) 2012-05-25 2018-02-28 The Regents of The University of California Procédés et compositions permettant la modification de l'adn cible dirigée par l'arn et la modulation de la transcription dirigée par l'arn
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
WO2015035168A1 (fr) * 2013-09-05 2015-03-12 Massachusetts Institute Of Technolgy Syntonisation du spectre d'hôtes bactériophages
CN107207614B (zh) * 2014-10-09 2022-01-11 利普泰克有限公司 嵌合蛋白
EP3234136B1 (fr) 2014-12-16 2024-08-21 C3J Therapeutics, Inc. Compositions et procédés de modification in vitro de génomes viraux

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012036580A2 (fr) * 2010-09-17 2012-03-22 Tecnifar-Indústria Técnica Farmacêutica, S.A. Phage antibactérien, peptides phagiques et leurs procédés d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LU TIMOTHY K ET AL: "<mark>Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy</mark>", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), vol. 106, no. 12, 1 March 2009 (2009-03-01), pages 4629 - 4634, XP093261368, ISSN: 0027-8424, DOI: 10.1073/pnas.0800442106 *
LU TIMOTHY K. ET AL: "Dispersing biofilms with engineered enzymatic bacteriophage", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), vol. 104, no. 27, 3 July 2007 (2007-07-03), pages 11197 - 11202, XP093261367, ISSN: 0027-8424, DOI: 10.1073/pnas.0704624104 *
TIMOTHY K LU ET AL: "The next generation of bacteriophage therapy", CURRENT OPINION IN MICROBIOLOGY, vol. 14, no. 5, 23 August 2011 (2011-08-23), pages 524 - 531, XP028312588, ISSN: 1369-5274, [retrieved on 20110730], DOI: 10.1016/J.MIB.2011.07.028 *

Also Published As

Publication number Publication date
US20160186147A1 (en) 2016-06-30
JP7133671B2 (ja) 2022-09-08
EP3234136A4 (fr) 2018-10-10
CN113215115A (zh) 2021-08-06
EA201791343A1 (ru) 2018-03-30
JP2021074024A (ja) 2021-05-20
US10837004B2 (en) 2020-11-17
US11913032B2 (en) 2024-02-27
US20190211312A1 (en) 2019-07-11
AU2022202713B2 (en) 2025-01-02
CN107278227A (zh) 2017-10-20
AU2022202713A1 (en) 2022-05-19
JP6842417B2 (ja) 2021-03-17
EA038595B1 (ru) 2021-09-21
CA3254091A1 (en) 2025-10-27
WO2016100389A1 (fr) 2016-06-23
EP4484556A2 (fr) 2025-01-01
US20210087538A1 (en) 2021-03-25
AU2015362618B2 (en) 2022-01-27
JP2017537643A (ja) 2017-12-21
US10711253B2 (en) 2020-07-14
EP3234136B1 (fr) 2024-08-21
HK1245838A1 (en) 2018-08-31
AU2015362618A1 (en) 2017-07-13
US10221398B2 (en) 2019-03-05
CN113215115B (zh) 2024-07-02
US20190322988A1 (en) 2019-10-24
CN107278227B (zh) 2021-05-28
CA2971205A1 (fr) 2016-06-23
ES2991077T3 (es) 2024-12-02
EP3234136A1 (fr) 2017-10-25

Similar Documents

Publication Publication Date Title
EP4484556A3 (fr) Compositions et procédés pour l&#39;ingénierie in vitro du génome viral
MX2025009289A (es) Inserciones de adn no virales orientadas
EP3699280A3 (fr) Nouveaux systèmes cas9 et procédés d&#39;utilisation
HK1253712A1 (zh) 使用crispr核酸筛选细菌、古细菌、藻类和酵母的方法
EP4282970A3 (fr) Ingénierie de génome humain guidée par arn
WO2014144592A3 (fr) Utilisation d&#39;arn de guidage tronqués (arng tron) pour une augmentation de la spécificité d&#39;édition génomique guidée par arn
WO2015191693A3 (fr) Procédé d&#39;édition génique
GEP20217251B (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2016057961A8 (fr) Compositions et procédés pour activer une réparation dirigée par homologie
WO2012142611A3 (fr) Séquençage de petites quantités d&#39;acides nucléiques complexes
EP4242321A3 (fr) Banques de gènes synthétisés de novo
WO2012167192A3 (fr) Procédés et produits pour la production de lignées cellulaires génétiquement modifiées de mammifère par des transgènes amplifiés
EP3382019A4 (fr) Procédé de conversion de séquence de génome de monocotylédone convertissant spécifiquement une base d&#39;acide nucléique d&#39;une séquence adn ciblée, et complexe moléculaire mettant en oeuvre celui-ci
WO2014039692A3 (fr) Loci de performance fad2 et protéines se liant à un site spécifique cible correspondantes pouvant induire des cassures ciblées
MX2021000211A (es) Metodos y productos para transfeccion de celulas.
NZ712727A (en) Compositions and methods of nucleic acid-targeting nucleic acids
HK1207111A1 (en) Methods and compositions for controlling gene expression by rna processing
MX2011012312A (es) Vacuna universal para influenza basada en virus vaccinia ankara (mva) modificado recombinante.
WO2013032850A3 (fr) Compositions et procédés pour un assemblage haute-fidélité d&#39;acides nucléiques
WO2018226972A3 (fr) Compositions et procédés pour l&#39;édition génomique
MX2021004455A (es) Composiciones y métodos para administrar transgenes.
MX2013002249A (es) Acidos nucleicos, composiciones y metodos para la escision de acidos nucleicos objetivos.
WO2011101811A3 (fr) Système amélioré de recombinaison méganucléase
WO2011022656A3 (fr) Vaccin recombinant contre le paramyxovirus aviaire, sa méthode de fabrication et d&#39;utilisation
WO2013083264A8 (fr) Adn polymérases présentant une activité améliorée

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3234136

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C12N0007010000

Ipc: C12N0015113000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 7/01 20060101ALI20250331BHEP

Ipc: C12N 9/22 20060101ALI20250331BHEP

Ipc: C12N 15/113 20100101AFI20250331BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 7/01 20060101ALI20250411BHEP

Ipc: C12N 9/22 20060101ALI20250411BHEP

Ipc: C12N 15/113 20100101AFI20250411BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40122397

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251107